PDCD1 and neoplasm: Therefore, we hypothesize that decreased muscle quality reflects an increased degree of tumor‐associated inflammation, which enhances the resistance against antitumor immunity and results in poor outcomes in PD‐1/PD‐L1‐targeted treatments.